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A novel type of encephalopathy associated with mushroom Sug-
ihiratake ingestion in patients with chronic kidney diseases.
Background. The etiology of encephalopathy in uremic pa-
tients is multiple. We recently encountered a novel type of
encephalopathy which occurred exclusively in patients with
chronic kidney diseases after ingestion of a mushroom called
Sugihiratake. While the exact etiology of this encephalopathy
remained mysterious, we aimed to describe its clinical features.
Methods. A total of 32 patients with chronic kidney diseases
who had presented with encephalopathy following ingestion of
Sugihiratake were enrolled from seven prefectures in Japan.,
with 24 of the 32 patients undergoing regular hemodialysis. The
patient’s clinical data were from surveillance by The Japanese
Society of Nephrology.
Results. There was a significant association between Sugihi-
ratake ingestion and the occurrence of encephalopathy in 524
hemodialysis patients questioned for a recent ingestion of this
mushroom (P = 0.0006). The latent asymptomatic period be-
fore the onset of symptoms varied from 1 to 31 days (mean 9.1 ±
7.3) days. The patient’s symptoms consisted of disturbed con-
sciousness in 30 patients (93.8%), convulsions in 25 (78.1%),
myoclonus in 15 (46.9%), dysarthria in ten (31.3%), ataxia in
eight (25.0%), paresis or paralysis in seven (21.9%), and skin
parasthesia in two patients (6.3%). Nine (27.2%) patients died,
mostly due to respiratory failure. The other patients were either
discharged or still in hospitals with various degrees of clinical
improvement.
Conclusion. Patients with chronic kidney diseases are at risk
of having serious encephalopathy following Sugihiratake inges-
tion and must refrain from eating it. Physicians, in those parts of
the world, where this mushroom harvesting is common, should
be aware of this complication.
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Sugihiratake (Fig. 1) is the Japanese name of the fun-
gus Pleurocybella porrigens, which is a small mushroom
that grows in abundance during the fall season, not only
in the forest of northern Japan, but is also widely dis-
tributed across the northern hemisphere [1]. It has an
interesting flavor that many Japanese used to enjoy, usu-
ally consumed as a component of the highly popular miso
(fermented bean paste) soup. Until now, there has been
no report of significant adverse effect as a result of Sug-
ihiratake ingestion. However, during the fall of 2004 in
Japan, an outbreak of a serious encephalopathy exclu-
sively occurred in patients with chronic kidney diseases
after ingestion of this mushroom.
While the exact etiology of the encephalopathy re-
mains mysterious and currently under investigation, we
wish to report for the first time the neurotoxic effects of P.
porrigens mushroom intoxication in a series of Japanese
patients with chronic kidney disease.
METHODS
Data used for this study were from surveillance by
The Japanese Society of Nephrology. From September
through October 2004, a total of 45 patients with chronic
kidney diseases presented to several hospitals in eight
prefectures in Japan (Fig. 2) because of acute neurologic
disturbances. Extensive workup to find out a possible
cause was negative other than a history of ingesting Sug-
ihiratake in 44 of the 45 patients during its harvesting
season from the end of August through October 2004.
Among the 44 patients, 32 (19 females and 13 males) who
had their clinical conditions reported to us by the physi-
cians in charge were enrolled in the analysis. Twenty-four
patients previously had received regular hemodialysis,
whereas eight were not yet undergoing dialysis. The mean
age of the patients was 69.2 ± 10.5 years. The underly-
ing kidney diseases were chronic glomerulonephritis in
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Fig. 1. Photographs of Sugihiratake (Pleurocybella porrigens). Sugihiratake have a habitat rooting on woods, especially Cryptomeria japonica in
Japan forming dense clusters (A). The mushroom, which the patient 1 (Table 2) ingested, was that of P. porrigens (B). The pileus of Sugihiratake,
also known as “angel’s wings,” was 3 to 5 inches long, white in color, and had a wavy margin (C).
14 patients, diabetic nephropathy in eight, unknown eti-
ology in five, hypertension in three, and polycystic kidney
disease in two patients. All patients, whether dialyzed or
not, were in stable clinical condition before this event.
We also questioned a total of 524 hemodialysis patients at
nine hospitals in the affected area for any recent history
of Sugihiratake ingestion and the intoxication rate was
calculated. Statistical analyses were conducted by Fisher
exact probability test with StatView 5.0 software (Abacus
Concepts, Inc., Berkeley, CA, USA).
RESULTS
All cases of acute encephalopathy after Sugihiratake
ingestion occurred in patients who had chronic kidney
diseases, whereas none of the individuals with normal re-
nal function who had eaten Sugihiratake were affected.
Out of 524 hemodialysis patients, 278 (53%) admitted
recent ingestion of Sugihiratake, but only 12 patients
(4.3%) manifested symptoms of intoxication. By Fisher’s
exact probability test, there was a highly significant asso-
ciation between the mushroom ingestion by hemodial-
ysis patients and the development of encephalopathy
(P = 0.0006).
The clinical profile, time of symptom onset, and the out-
come are listed in Table 1 for the patients on hemodial-
ysis, and in Table 2 for the patients with pre-end-stage
renal disease (pre-ESRD). Nine (28.1%) patients had
died so far, five had been uneventfully discharged, and
the other 18 patients have remained hospitalized with
various degrees of clinical improvement. While many pa-
tients continued to eat the mushroom for several days
before the symptoms appeared, the time from the start
of ingestion to onset of symptoms varied from 1 to 31
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Fig. 2. The distribution of the cases with
acute neurological disturbaces. Cases in-
cluded in the analysis () (N = 32). Cases not
included in the analysis because of insufficient
clinical information () (N = 12).
days (9.1 ± 7.3 days), with no difference between the
patients who died or survived. The most common symp-
toms in all 32 patients included disturbed consciousness
of various degrees in 30 patients (93.8%), convulsions
in 25 (78.1%), myoclonus in 15 (46.9%), dysarthria in
ten (31.3%), ataxia in eight (25.0%), paresis or paraly-
sis in seven (21.9%), and skin parasthesia in two patients
(6.3%). Typically, most patients presented initially with
ataxia and/or myoclonus several days after Sugihiratake
injestion, to be followed in a few days by generalized con-
vulsions. The convulsive activities either stopped without
neurologic sequelae or progressed to status epilipticus
and death. The terminal event was profound central ap-
nea and bradycardia. Noteworthy, all patients did not ex-
perience gastrointestinal symptoms, which are generally
common features of mushroom poisoning. Fever was un-
detectable in almost all patients at the initial presentation;
however, some patients had their temperature increased
after admission secondary to a respiratory infection.
After being admitted, the patients were closely moni-
tored either in a general ward or in an intensive care unit
with the support of a neurologist. The differential diagno-
sis included metabolic encephalopathy, cerebrovascular
accident, viral encephalitis, or possible drug intoxication.
Nineteen patients underwent computerized tomographic
(CT) brain scans to role out stroke, but no organic lesion
could be identified, though in five patients, who ultimately
died, brain edema was evident. Lumber puncture was
done in ten patients, and the cerebrospinal fluid analy-
sis showed a mild increase of protein content, but normal
cell count and sugar. There were no significant changes in
the blood biochemistry, including blood sugar, liver func-
tion tests, serum aluminum levels, and blood gas analysis
compared with the preintoxication levels in most patients.
Treatment depended on the severity of presenting
symptoms. Fourteen patients on regular hemodialysis,
and two other patients who are not yet on hemodial-
ysis, were assigned to every-other-day dialysis. Ten pa-
tients with more severe mental confusion were managed
in an intensive care unit with continuous venovenous
hemodialysis (CVVHD) and mechanical ventilatory sup-
port. Nine patients died 4 to 15 days (mean 8.2 ± 4.1 days)
after admission. The principal characteristics of these pa-
tients were severe mental confusion in all and convulsive
activities in eight.
DISCUSSION
Acute encephalopathy specifically related to pa-
tients with uremia may result from any of the fol-
lowing causes; uremic encephalopathy, dialysis dysequi-
librium syndrome, cerebrovascular disease, electrolytes
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Table 1. Clinical characteristics and outcome of the patients undergoing hemodialysis
Duration of Onset of
hemodialysis symptoms
Patients Age Gender years daysa Symptomsb Outcomec
1 69 F 5 1 1, 2 Died
2 60 F 8 10 1, 3 In hospital
3 62 F 8 11 1, 2,4, 7 In hospital
4 65 F 8 3 1, 2, 3 In hospital
5 70 F 15 14 1, 2,3, 6 In hospital
6 77 F 5 ND 1, 3, 5 Discharged
7 57 F 5 14 1, 2, 4, 5 In hospital
8 66 F 10 ND 1, 2, 3 In hospital
9 58 F 4 14 1, 2, 6 In hospital
10 60s F 0.3 12 1, 2, 3 In hospital
11 72 F 2 13 1, 2, 6 In hospital
12 71 F 11 ND 1, 4, 6, 7 In hospital
13 72 F 3 4 1, 2, 4, 6 Died
14 48 F 20 ND 1, 2 Died
15 85 M 1 18 1, 2, 3 In hospital
16 68 M 6 12 1, 2, 4, 5 In hospital
17 78 M 1 31 1, 2, 3 In hospital
18 66 M 3 14 1, 2, 3, 5, 6 Died
19 73 M 1.8 14 1, 2, 3, 4 Died
20 64 M 7 ND 4, 6 Discharged
21 50 M 0.3 1 1, 2, 3 Discharged
22 53 M 16 3 1, 2 Died
23 83 M 1.5 ND 1, 2 Died
24 60 M 2 7 1, 2, 3, 4 In hospital
Abbreviations are: F, female; M, male; ND, not determined.
aTime of symptom onset after Sugihiratake ingestion.
b1, disturbed consciousness; 2, convulsions; 3, myoclonus; 4, dysarthria; 5, ataxia; 6, paresis/paralysis; 7, parasthesias.
cAs confirmed by the end of October 2004.
Table 2. Clinical characteristics of the patients with pre-end-stage renal disease (pre-ESRD)
Serum Onset of
creatinine symptoms
Patients Age Gender mg/dL daysa Symptomsb Outcomec
1 87 F 4.8 3 1, 2, 3, 4, 5 Discharged
2 68 F 5.6 ND 1, 5 Died
3 71 F 5.5 7 1, 2, 5 Died
4 84 F 6.2 2 1, 4 In hospital
5 80 F 1.5 1 1, 2, 3 In hospital
6 89 M 2.0 ND 1, 2, 5 In hospital
7 71 M 4.0 8 1, 2 In hospital
8 67 M 8.0 20 3 Discharged
Abbreviations are: F, female; M, male; ND, not determined
aTime of symptom onset after Sugihiratake ingestion.
b1, disturbed consciousness; 2, convulsions; 3, myoclonus; 4, dysarthria; 5, ataxia; 6, paresis/paralysis; 7, parasthesias
cAs confirmed by the end of October 2004.
disorders, and aluminum intoxication [2]. Because of the
impaired excretory function, uremic patients are also es-
pecially vulnerable to drugs and toxins from many dif-
ferent sources, including food. There have been reports
of encephalopathy in uremic patients caused by star fruit
(Averrhoa carambola) intoxication [3, 4]. However, acute
encephalopathy related to mushroom poisoning in ure-
mic patients have not been previously reported.
Two theories for the etiology of this encephalopathy
have been speculated. The first theory suggested that an
aberrant viral infection, to which uremic patients par-
ticularly susceptible, is to be the culprit. However, the
absence of family history of similar symptoms, fever, or
other markers of acute inflammatory response, in addi-
tion to the lack of cerebrospinal fluid pleocytosis stood
against this theory. Moreover, the examination for com-
mon viral infections was negative. The second theory ac-
cused a toxin that is normally metabolized through the
kidney. Reviewing the history for a possible intoxication
disclosed that almost all of the patients had eaten Sugihi-
ratake. Statistical analysis of hemodialysis patients in the
affected area indicated a significant association between
Sugihiratake ingestion and the intoxication episodes. Al-
though these findings suggest a causal connection, several
questions remained to be answered. If the mushroom is
to blame, then, why intoxication occurred this year only,
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and why only a small percentage of hemodialysis patients
who took the mushroom turned to be symptomatic? What
was the nature of this toxin, and how did it cause the en-
cephalopathy?
Despite the fact that wild mushrooms are collected and
consumed, becoming poisoned is still a probability. It is
well-known that even some experts have difficulty in dis-
criminating between the mushrooms. The extremely wet
and hot regional weather in 2004 may have boosted the
growth of some poisonous species that are morpholog-
ically indistinguishable from the benign mushrooms. In
fact, an exceptionally good harvest of Sugihiratake was
reported in the affected areas, suggesting that somewhat
change in property of the mushroom occurred in this sea-
son. In addition, this may support that the amount of in-
gested mushroom was higher in 2004 than previous years.
The toxic characteristics of a mushroom may vary from
region to another depending on the soil type [5], and the
individual response to certain fungal toxins is also very
variable [6]. Taken together, these factors may explain
why only limited number of hemodialysis patients were
affected.
The connection of the encephalopathy to mushroom
poisoning in our series was particularly difficult because
of the extraordinary long latent period, and the lack of di-
gestive and hepatic abnormalities, nonetheless, this pos-
sibility was worth considered after excluding the other
common causes of encephalopathy in uremic patients.
In orellanine-containing mushrooms, a latent period of
36 hours to 17 days postingestion is usual before the
onset of symptoms, although the clinical symptoms are
incompatible [7]. The presentation of mushroom poison-
ing generally depends on the species and the amount in-
gested. Encephalopathy was the hallmark of Sugihiratake
mushroom poisoning. The fact that hemodialysis was in-
efficient in preventing the encephalopathy in our series
is probably because the elimination capacity was over-
whelmed by the amount ingested. Alternatively, it may
suggest that the molecular size of the toxin was not small
enough to dialyze or that the toxin could have passed
the blood-brain barriers, and hence became inaccessi-
ble for dialysis. This may be an important contributing
factor to its neurotoxic effect. The permeability of the
blood brain barrier may have been increased by chemi-
cal mediators and cytokines [8]. Experiments to identify
and isolate the specific toxin in the mushroom are still
undergoing.
In this report, we warn practicing nephrologists that
mushroom poisoning must be considered when patients
with chronic renal diseases present with conscious distur-
bances and unexplained neurologic symptoms.
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